Net loss for the three months ended March 31, 2026, was $1.0 million, compared to $3.9 million in the same period of 2025. Operating expenses decreased significantly to $0.9 million from $3.0 million in Q1 2025, driven by cost-reduction efforts and staff terminations. Cash position improved to $5.4 million as of March 31, 2026, primarily due to $7.3 million in gross proceeds from equity issuances. The company is currently trading on the OTC Pink Limited tier following its delisting from Nasdaq in February 2026. Management has concluded there is substantial doubt regarding the company's ability to continue as a going concern.